• 1
    Cesaretti JA, Stone NN, Skouteris VM, Park JL, Stock RG. Brachytherapy for the treatment of prostate cancer. Cancer J 2007; 13: 30212
  • 2
    Zelefsky MJ, Yamada Y, Pei X et al. Comparison of tumor control and toxicity outcomes of high-dose intensity-modulated radiotherapy and brachytherapy for patients with favorable risk prostate cancer. Urology 2011; 77: 98690
  • 3
    Sanda MG, Dunn RL, Michalski J et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 2008; 358: 125061
  • 4
    Stone NN, Stock RG. Long-term urinary, sexual, and rectal morbidity in patients treated with iodine-125 prostate brachytherapy followed up for a minimum of 5 years. Urology 2007; 69: 33842
  • 5
    Keyes M, Miller S, Moravan V et al. Urinary symptom flare in 712 125I prostate brachytherapy patients: long-term follow-up. Int J Radiat Oncol Biol Phys 2009; 75: 64955
  • 6
    Talcott JA, Manola J, Clark JA et al. Time course and predictors of symptoms after primary prostate cancer therapy. J Clin Oncol 2003; 21: 397986
  • 7
    Pieters BR, Rezaie E, Geijsen ED et al. Development of late toxicity and International Prostate Symptom Score resolution after external-beam radiotherapy combined with pulsed dose rate brachytherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2011; 81: 75864
  • 8
    Mohammed N, Kestin L, Ghilezan M et al. Comparison of acute and late toxicities for three modern high-dose radiation treatment techniques for localized prostate cancer. Int J Radiat Oncol Biol Phys 2012; 82: 20412
  • 9
    Zagar TM, Stock RG, Cesaretti JA, Stone NN. Assessment of postbrachytherapy sexual function: a comparison of the IIEF-5 and the MSEFS. Brachytherapy 2007; 6: 2633
  • 10
    Stock RG, Stone NN, Iannuzzi C. Sexual potency following interactive ultrasound-guided brachytherapy for prostate cancer. Int J Radiat Oncol Biol Phys 1996; 35: 26772
  • 11
    Stock RG, Stone NN, Cesaretti JA, Rosenstein BS. Biologically effective dose values for prostate brachytherapy: effects on PSA failure and posttreatment biopsy results. Int J Radiat Oncol Biol Phys 2006; 64: 52733
  • 12
    Eifel PJ, Levenback C, Wharton JT, Oswald MJ. Time course and incidence of late complications in patients treated with radiation therapy for FIGO stage IB carcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys 1995; 32: 1289300
  • 13
    Langberg CW, Hauer-Jensen M. Influence of fraction size on the development of late radiation enteropathy. An experimental study in the rat. Acta Oncol 1996; 35: 8994
  • 14
    Forsythe K, Blacksburg S, Stone N, Stock RG. Intensity-modulated radiotherapy causes fewer side effects than three-dimensional conformal radiotherapy when used in combination with brachytherapy for the treatment of prostate cancer. Int J Radiat Oncol Biol Phys 2012; 83: 6305
  • 15
    Prada PJ, Fernandez J, Martinez AA et al. Transperineal injection of hyaluronic acid in anterior perirectal fat to decrease rectal toxicity from radiation delivered with intensity modulated brachytherapy or EBRT for prostate cancer patients. Int J Radiat Oncol Biol Phys 2007; 69: 95102
  • 16
    Park DS, Morris EJ, Stefanis L et al. Multiple pathways of neuronal death induced by DNA-damaging agents, NGF deprivation, and oxidative stress. J Neurosci 1998; 18: 83040
  • 17
    Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994; 151: 5461
  • 18
    Emara AM, Chadwick E, Nobes JP, Abdelbaky AM, Laing RW, Langley SE. Long-term toxicity and quality of life up to 10 years after low-dose rate brachytherapy for prostate cancer. BJU Int 2012; 109: 9941000